Brooklyn Investment Group Invests $167,000 in DaVita Inc. (NYSE:DVA)

Brooklyn Investment Group bought a new stake in shares of DaVita Inc. (NYSE:DVA) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 1,017 shares of the company’s stock, valued at approximately $167,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Quantbot Technologies LP bought a new stake in DaVita in the 3rd quarter valued at $8,925,000. FMR LLC lifted its stake in shares of DaVita by 659.9% in the third quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after buying an additional 154,061 shares during the period. Bank of Montreal Can grew its position in DaVita by 0.9% during the third quarter. Bank of Montreal Can now owns 60,929 shares of the company’s stock worth $9,936,000 after buying an additional 520 shares in the last quarter. Harvest Fund Management Co. Ltd increased its stake in DaVita by 14.4% during the third quarter. Harvest Fund Management Co. Ltd now owns 11,142 shares of the company’s stock valued at $1,826,000 after acquiring an additional 1,399 shares during the period. Finally, Daiwa Securities Group Inc. raised its holdings in DaVita by 6.0% in the 3rd quarter. Daiwa Securities Group Inc. now owns 6,187 shares of the company’s stock valued at $1,014,000 after acquiring an additional 348 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at approximately $138,284,666.75. This represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.00% of the company’s stock.

DaVita Trading Down 1.3 %

Shares of DaVita stock opened at $165.71 on Thursday. The stock has a market capitalization of $13.59 billion, a P/E ratio of 17.88, a price-to-earnings-growth ratio of 0.94 and a beta of 0.89. DaVita Inc. has a 12-month low of $98.26 and a 12-month high of $169.51. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The company has a 50-day simple moving average of $158.42 and a 200 day simple moving average of $148.87.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The firm had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business’s revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.85 EPS. Research analysts expect that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on DVA. UBS Group lifted their price objective on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Barclays boosted their price target on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Bank of America lifted their target price on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. Finally, Truist Financial increased their price target on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.